| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT05669664 Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary… |
date change Primary completion moved earlier: 2027-04-11 -> 2026-11-30 |
| 2026-06-12 | NCT05669664 Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary… |
date change Completion moved earlier: 2027-04-11 -> 2026-11-30 |
| 2026-06-10 | NCT06592924 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration… |
Trial sites expanded: 340 -> 368 locations |
| 2026-06-09 | NCT06855277 Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With… |
Trial sites expanded: 55 -> 69 locations |
| 2026-06-05 | NCT07287150 A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant… |
Trial sites expanded: 20 -> 32 locations |
| 2026-06-05 | NCT07213674 A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With… |
Trial sites expanded: 129 -> 133 locations |
| 2026-06-04 | NCT03419234 Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone… |
date change Completion pushed: 2026-04-01 -> 2028-04-01 |
| 2026-06-04 | NCT05797168 Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With… |
Trial arms changed: 5 -> 6 |
| 2026-06-04 | NCT06136650 A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA)… |
Trial sites expanded: 324 -> 327 locations |
| 2026-06-03 | NCT07226986 A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan… |
Trial sites expanded: 12 -> 17 locations |
| 2026-06-03 | NCT07190300 TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With… |
Trial sites expanded: 25 -> 29 locations |
| 2026-06-03 | NCT03732820 Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic… |
date change Completion pushed: 2026-04-27 -> 2027-02-05 |
| 2026-05-28 | NCT06120491 Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-28 | NCT06120491 Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate… |
Trial sites reduced: 410 -> 322 locations |
| 2026-05-28 | NCT06120491 Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate… |
date change Primary completion moved earlier: 2028-01-11 -> 2027-09-30 |
| 2026-05-28 | NCT05849298 A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With… |
Trial sites reduced: 41 -> 37 locations |
| 2026-05-23 | NCT03860987 Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using… |
Trial completed |
| 2026-05-23 | NCT03860987 Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using… |
date change Primary completion moved earlier: 2026-07-31 -> 2026-05-11 |
| 2026-05-23 | NCT03860987 Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using… |
date change Completion moved earlier: 2028-08-01 -> 2026-05-18 |
| 2026-05-16 | NCT06691984 Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy… |
overall status: "Recruiting" → "Active Not Recruiting" |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07641855 A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant… | Phase 2/3 | Not Yet Recruiting |
| 2026-06-02 | NCT07620041 QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug… | Phase 1 | Not Yet Recruiting |
| 2026-06-02 | NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… | Phase 3 | Not Yet Recruiting |
| 2026-06-01 | NCT07617272 Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting… | Phase 2 | Recruiting |
| 2026-05-28 | NCT07611110 AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant… | Phase 3 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05348876 | A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real… | Non-metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT06660862 | Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in… | Prostate Cancer | Not Yet Recruiting |
| NCT03016741 | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | Castration-Resistant Prostatic Cancer | Active, Not Recruiting |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With… | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting |
| Phase 3 | |||
| NCT06470243 | Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will… | Castration-Resistant Prostate Carcinoma | Recruiting |
| NCT06650579 | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | Recurrent Prostate Carcinoma | Recruiting |
| NCT04916613 | ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable… | Prostate Cancer Metastatic | Recruiting |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Prostate Cancer Metastatic | Recruiting |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice… | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT06380751 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine… | Advanced Breast Cancer | Recruiting |
| NCT06952803 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT… | Prostate Cancer | Recruiting |
| NCT06520345 | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT… | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant… | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With… | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA)… | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration… | Prostate Cancer (Adenocarcinoma) | Recruiting |
| NCT06855277 | Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With… | Prostate Cancer | Recruiting |
| NCT04647526 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line… | Metastatic Castration-Resistant Prostate Cancer | Active, Not Recruiting |
| NCT05171816 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic… | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting |
| NCT04464226 | Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in… | Cancer | Active, Not Recruiting |
| NCT05050084 | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less… | Prostate Adenocarcinoma | Active, Not Recruiting |
| NCT04484818 | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy… | Prostate Carcinoma | Active, Not Recruiting |
| NCT04493853 | Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive… | Hormone-Sensitive Prostate Cancer | Active, Not Recruiting |
| NCT04136353 | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate | Prostate Cancer | Active, Not Recruiting |
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy… | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting |